According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Poviztra is a second brand of Wegovy
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
